Literature DB >> 32738586

Cognitive and linguistic outcomes after awake craniotomy in patients with high-grade gliomas.

S Bonifazi1, C Passamonti2, S Vecchioni3, R Trignani3, P P Martorano4, V Durazzi5, S Lattanzi5, F Mancini6, R A Ricciuti6.   

Abstract

BACKGROUND: Preservation of language and cognition is crucial in glioma surgery, as they are crucial aspects of daily life functioning. Several studies claimed that awake surgery in eloquent areas is demanded in low and high-grade gliomas. Cognitive and language outcome has been less investigated in high-grade gliomas compared to low-grade.
METHOD: We analyzed the neuropsychological and neuro-oncological outcome of nineteen patients (from a cohort of forty patients) who underwent fully awake surgery for resection of malignant tumors located in eloquent areas.
RESULTS: Post-surgery, linguistic functions were unchanged in 80 % of patients. Slight impairments in memory and executive functions were observed in about 50 % of patients. Survival rate at one year follow-up was 89 %. Results showed that awake procedure is safe, well tolerated and related with good linguistic outcome similar to low-grade gliomas. The majority of patients reported a good outcome in term of quality of life.
CONCLUSIONS: Our results confirm that awake surgery is associated to good cognitive and linguistic clinical outcome also in malignant tumors.
Copyright © 2020 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Awake surgery; Brain tumor; Direct electrical stimulation; Neuropsychological outcome

Mesh:

Year:  2020        PMID: 32738586     DOI: 10.1016/j.clineuro.2020.106089

Source DB:  PubMed          Journal:  Clin Neurol Neurosurg        ISSN: 0303-8467            Impact factor:   1.876


  1 in total

1.  A Novel Language Paradigm for Intraoperative Language Mapping: Feasibility and Evaluation.

Authors:  Katharina Rosengarth; Delin Pai; Frank Dodoo-Schittko; Katharina Hense; Teele Tamm; Christian Ott; Ralf Lürding; Elisabeth Bumes; Mark W Greenlee; Karl Michael Schebesch; Nils Ole Schmidt; Christian Doenitz
Journal:  J Clin Med       Date:  2021-02-08       Impact factor: 4.241

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.